Including panobinostat in a regimen that included bortezomib and dexamethasone improved median PFS to 11.9 months as compared with 8.08 months in the control arm.
The addition of panobinostat to bortezomib and dexamethasone significantly extended PFS among patients with relapsed or relapsed/refractory multiple myeloma, according to results of the randomized phase 3 PANORAMA1 trial.
Preclinical studies showed panobinostat (LBH589, Novartis) — an oral pan-deacetylase inhibitor — has anti-myeloma activity when combined with bortezomib (Velcade, Millennium) and dexamethasone.
In the current study, Jesús F. San-Miguel, MD, PhD, head of the department of hematology at the University Hospital of Salamanca in Spain, and colleagues sought to compare bortezomib, dexamethasone and panobinostat with bortezomib, dexamethasone and placebo.
The analysis included 768 patients (median age, 63 years) with relapsed or relapsed/refractory multiple myeloma. About half of patients (48%) had received two or three prior regimens, and 57% had undergone prior autologous stem cell transplant.
Read the complete report on Healio: http://bit.ly/1wjWYoY
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More